Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells

Anti-Cancer Drugs

Volumn 25, Issue 3, 2014, Pages 282-288

  Wang, Xiangling ^a   Feng, Xiaoli ^a   Wang, Juandong ^a   Shao, Na ^b   Ji, Chunyan ^b   Ma, Daoxin ^b   Henter, Jan Inge ^c   Fadeel, Bengt ^d   Zheng, Chengyun ^a,c  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Bortezomib; Combination therapy; Interleukin 12; Multiple myeloma; Natural killer cells; Proteasome inhibitor

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; KILLER CELLS, NATURAL; MALE; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PYRAZINES;

EID: 84895073932     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000058     Document Type: Article

References (35)

1. Lemaire M, Deleu S, De Bruyne E, Van Valckenborgh E, Menu E, Vanderkerken K. The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res 2011; 110: 19-42.
2. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. Proteasome inhibitors: antitumor effects and beyond. Leukemia 2007; 21: 30-36.
3. McBride A, Ryan PY. Proteasome inhibitors in the treatment of multiple myeloma. Expert Rev Anticancer Ther 2013; 13: 339-358.
4. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116: 4745-4753.
5. Painuly U, Kumar S. Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. Clin Med Insights Oncol 2013; 7: 53-73.
6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
7. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
8. Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010; 11: 934-941.
9. Zeng Z, Lin J, Chen J. Bortezomib for patients with previously untreated multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Ann Hematol 2013; 92: 935-943.
10. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factorrelated apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006; 66: 7317-7325.
11. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood 2008; 111: 1309-1317.
12. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008; 180: 163-170.
13. Ames E, Hallett WH, Murphy WJ. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol 2009; 155: 504-513.
14. Smyth MJ, Cretney E, Kelly JM, Westwood JA, Street SE, Yagita H, et al. Activation of NK cell cytotoxicity. Mol Immunol 2005; 42: 501-510.
15. Godfrey J, Benson DM Jr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma 2012; 53: 1666-1676.
16. Wang X, Ottosson A, Ji C, Feng X, Nordenskjöld M, Henter JI, et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 2009; 94: 470-478.
17. Iwata S, Yano S, Ito Y, Ushijima Y, Gotoh K, Kawada J, et al. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Int J Cancer 2011; 129: 2263-2273.
18. Shen L, Au WY, Guo T, Wong KY, Wong ML, Tsuchiyama J, et al. Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood 2007; 110: 469-470.
19. Feng X, Yan J, Wang Y, Zierath JR, Nordenskjöld M, Henter JI, et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol 2010; 47: 2388-2396.
20. Airoldi I, Cocco C, Giuliani N, Ferrarini M, Colla S, Ognio E, et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008; 112: 750-759.
21. Tasaki K, Yoshida Y, Maeda T, Miyauchi M, Kawamura K, Takenaga K, et al. Protective immunity induced in murine colon carcinoma cells by the expression of interlrukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther 2000; 7: 247-254.
22. Wen XY, Mandelbaum S, Li ZH, Hitt M, Graham FL, Hawley TS, et al. Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherapy of cancer: preclinical studies in myeloma. Cancer Gene Ther 2001; 8: 361-370.
23. Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol 2004; 125: 743-748.
24. Kodama T, Takeda K, Shimozato O, Hayakawa Y, Atsuta M, Kobayashi K, et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J lmmunol 1999; 29: 1390-1396.
25. Schwartz Y, Avraham R, Benish M, Rosenne E, Ben-Eliyahu S. Prophylactic IL-12 treatment reduces postoperative metastasis: mediation by increased numbers but not cytotoxicity of NK cells. Breast Cancer Res Treat 2008; 107: 211-223.
26. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010; 36: 274-288.
27. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin12. Cancer Res 2000; 60: 1111-1116.
28. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995; 87: 581-586.
29. Sgadari C, Angiolillo AL, Tostato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10. Blood 1996; 87: 3877-3882.
30. Straube C, Wehner R, Wendisch M, Bornhäuser M, Bachmann M, Rieber EP, et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007; 21: 1464-1471.
31. Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007; 6: 644-654.
32. He JD, Luo HL, Li J, Feng WT, Chen LB. Influences of the interferon induced transmembrane protein 1 on the proliferation, invasion, and metastasis of the colorectal cancer SW480 cell lines. Chin Med J (Engl) 2012; 125: 517-522.
33. Maseda D, Meister S, Neubert K, Herrmann M, Voll RE. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ 2008; 15: 600-612.
34. Uy GL, Peles S, Fisher NM, Tomasson MH, DiPersio JF, Vij R. Bortezomib prior to autologous transplant in multiple myeloma: effects on mobilization, engraftment, and markers of immune function. Biol Blood Marrow Transplant 2006; 12:116 (Abstract 331).
35. Burdelya L, Catlett-Falcone R, Levitzki A, Cheng F, Mora LB, Sotomayor E, et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther 2002; 1: 893-899.